NCT02332668 2026-03-16
MK-3475-051
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
12 trialsNCT07302347 2026-03-03
MK-3475-G21
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT03990961 2026-02-20
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
University of Chicago
Phase 2 Terminated
NCT06475235 2026-02-20
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT03445858 2026-02-18
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Children's Hospital Medical Center, Cincinnati
Phase EARLY_PHASE1 Completed
NCT03316573 2026-02-10
Pembrolizumab in Neoplasms or Lymphomas
Dana-Farber Cancer Institute
Phase 2 Suspended
NCT03829254 2026-01-12
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
NuCana plc
Phase 1/2 Recruiting
NCT03010176 2025-10-29
MK-1454-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03179930 2025-07-23
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03884556 2025-07-02
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT03995147 2025-06-08
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
University of Chicago
Phase 2 Active not recruiting
NCT03983668 2025-04-24
CMP-001 for Relapsed and Refractory Lymphoma
University of Iowa
Phase 1/2 Completed